NCT02681991 is a Phase 4 clinical trial of Renamezin capsule in Chronic Renal Failure, sponsored by Daewon Pharmaceutical Co., Ltd..

Who is sponsoring NCT02681991?

NCT02681991 is sponsored by Daewon Pharmaceutical Co., Ltd..

What drugs are being tested in NCT02681991?

Interventions in NCT02681991: Renamezin capsule.

What condition does NCT02681991 study?

NCT02681991 studies Chronic Renal Failure.

Is NCT02681991 still recruiting?

NCT02681991 is currently completed. Last updated 4 July 2017.

Last reviewed 2017-07-04 · How we verify

NCT02681991

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.

Completed Phase 4 Last updated 4 July 2017

What this trial tests

Phase 4 trial testing Renamezin capsule in Chronic Renal Failure in 110 participants. Completed in 1 September 2016.

Timeline

1 January 2016

Primary endpoint
1 September 2016

1 September 2016

Quick facts

Lead sponsor	Daewon Pharmaceutical Co., Ltd.
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	110
Start date	1 January 2016
Primary completion	1 September 2016
Estimated completion	1 September 2016
Sites	1 location across South Korea

Drugs / interventions tested

Renamezin capsule — full drug profile →

Conditions studied

Chronic Renal Failure — all drugs for Chronic Renal Failure →

Sponsor

Daewon Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 19 to 80, any sex, with Chronic Renal Failure. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

change from baseline of Indoxyl sulfate at 8weeks
Time frame: 0, 8weeks

Sponsor's own description

Renamezin Capsule (an oral adsorbent) lowers indoxyl sulfate levels in patient with chronic renal failure. 120 patients with chronic renal failure(baseline serum creatinine:1.5-5.0mg/dl). Renamezin is administered 6.0mg/day. The treatment period is 2 months. The change in serum indoxyl sulfate will be evaluated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study.
Kim SH, Jhee JH, Choi HY, Lee SH, et al · · 2020 · cited 4× · PMID 32736531 · DOI 10.1186/s12882-020-01971-x

Verify or expand the search:

Other recruiting trials for Chronic Renal Failure

Currently open trials in the same condition.

NCT06227468 — A Clinical Study to Map the HLA Genomic Region in the Greek Population · recruiting
NCT06347029 — Evaluation of Endothelial Dysfunction Using the "Flow Mediated Dilation" Test in a Population of Chronic Renal Failure P · NA · recruiting
NCT05884866 — A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to B · Phase 2 · recruiting
NCT05353946 — Coronary Rotational Atherectomy Elective vs. Bailout in Severely Calcified Lesions and Chronic Renal Failure · NA · recruiting

Other Daewon Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07364851 — A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunt · Phase 1 · not yet recruiting
NCT07349589 — Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers · Phase 1 · not yet recruiting
NCT07364877 — A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult Volunteers · Phase 1 · enrolling by invitation
NCT07343245 — A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs · Phase 1 · recruiting
NCT07319559 — Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02681991 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daewon Pharmaceutical Co., Ltd.
Last refreshed: 4 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02681991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing